LEVOTHYROXINE SODIUM

At a glance

Key dates

1. Approval

   FDA approval date of this drug product.

   Mar 05, 2025

   1 yr 4 mo ago

2. Today

Pharmaceutical detail

Generic (ANDA) of LEVOTHYROXINE SODIUM

• ERMEZABrand (NDA)

  NDA 215809 · MYLAN

  2022
• LEVOTHYROXINE SODIUMBrand (NDA)

  NDA 214253 · HIKMA

  2021
• THYQUIDITYBrand (NDA)

  NDA 214047 · STEVENS J

  2020
• LEVOTHYROXINE SODIUMBrand (NDA)

  NDA 210632 · FRESENIUS KABI USA

  2019
• TIROSINT-SOLBrand (NDA)

  NDA 206977 · IBSA

  2016
• LEVOTHYROXINE SODIUMBrand (NDA)

  NDA 202231 · FRESENIUS KABI USA

  2011
• TIROSINTBrand (NDA)

  NDA 021924 · IBSA

  2007
• LEVOLETBrand (NDA)

  NDA 021137 · GENUS LIFESCIENCES

  2003
• THYRO-TABSBrand (NDA)

  NDA 021116 · ALVOGEN

  2002
• SYNTHROIDBrand (NDA)

  NDA 021402 · ABBVIE

  2002
• EUTHYROXBrand (NDA)

  NDA 021292 · EMD SERONO INC

  2002
• LEVO-TBrand (NDA)

  NDA 021342 · CEDIPROF INC

  2002

Listed patents

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.